Our study uncovered a novel mechanism, the HBp/FOXO3/miRNA-30b-5p/MINPP1 axis, contributing to the development of HBV-positive HCC through the glycolytic bypass, and suggested miRNA-30b-5p/MINPP1 as a potential target for treatment strategy against HBV-related HCC. This evidence concerns the gene MINPP1 and hepatocellular carcinoma.